Zentalis Pharmaceuticals IncNASDAQ:ZNTL
- LAST PRICE3.8350
- TODAY'S CHANGE (%)0.1450 (3.9295%)
- Bid / Lots3.8300/ 5
- Ask / Lots3.8400/ 2
- Open / Previous Close3.7600 / 3.6900
- Day Range
- 52 Week Range
- Volume274,267
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ZNTL |
|---|---|---|
| 09:32 ET | 5838 | 3.735 |
| 09:34 ET | 500 | 3.73 |
| 09:36 ET | 300 | 3.77 |
| 09:38 ET | 3549 | 3.76 |
| 09:39 ET | 2628 | 3.8 |
| 09:41 ET | 3896 | 3.76 |
| 09:43 ET | 1413 | 3.75 |
| 09:45 ET | 400 | 3.75 |
| 09:48 ET | 1100 | 3.75 |
| 09:50 ET | 20400 | 3.7502 |
| 09:52 ET | 17370 | 3.76 |
| 09:54 ET | 11500 | 3.73 |
| 09:56 ET | 2285 | 3.776332 |
| 09:57 ET | 4567 | 3.74 |
| 09:59 ET | 5700 | 3.74 |
| 10:01 ET | 8320 | 3.75 |
| 10:03 ET | 2378 | 3.74 |
| 10:06 ET | 800 | 3.75 |
| 10:08 ET | 14163 | 3.74 |
| 10:10 ET | 1332 | 3.745 |
| 10:12 ET | 2829 | 3.75 |
| 10:14 ET | 3351 | 3.74 |
| 10:15 ET | 466 | 3.7447 |
| 10:17 ET | 1987 | 3.75 |
| 10:19 ET | 1300 | 3.74 |
| 10:21 ET | 1695 | 3.74 |
| 10:24 ET | 12284 | 3.775 |
| 10:26 ET | 13058 | 3.765 |
| 10:28 ET | 7308 | 3.76 |
| 10:30 ET | 7195 | 3.765 |
| 10:32 ET | 3526 | 3.75 |
| 10:33 ET | 3200 | 3.745 |
| 10:35 ET | 6917 | 3.76 |
| 10:37 ET | 3000 | 3.775 |
| 10:39 ET | 12311 | 3.76 |
| 10:42 ET | 1100 | 3.755 |
| 10:44 ET | 2001 | 3.765 |
| 10:46 ET | 800 | 3.79 |
| 10:48 ET | 1657 | 3.81 |
| 10:50 ET | 3306 | 3.82 |
| 10:51 ET | 7168 | 3.805 |
| 10:53 ET | 710 | 3.805 |
| 10:55 ET | 610 | 3.805 |
| 10:57 ET | 348 | 3.8 |
| 11:00 ET | 1000 | 3.81 |
| 11:02 ET | 2300 | 3.81 |
| 11:04 ET | 300 | 3.82 |
| 11:06 ET | 200 | 3.81 |
| 11:08 ET | 4253 | 3.85 |
| 11:09 ET | 1100 | 3.85 |
| 11:11 ET | 256 | 3.835 |
Sep 16, 2024
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm, from 9:38PM ET on Monday Sep 16, 2024 by Dow Jones
9:38PM ET on Monday Sep 16, 2024 by Dow JonesDJ Zentalis Pharmaceuticals Price Target Maintained With a $20.00/Share by Oppenheimer, from 2:03PM ET on Monday Sep 16, 2024 by Dow Jones
2:03PM ET on Monday Sep 16, 2024 by Dow JonesDJ Zentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib Studies, from 7:37AM ET on Monday Sep 16, 2024 by Dow Jones
7:37AM ET on Monday Sep 16, 2024 by Dow JonesZentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies, from 7:00AM ET on Monday Sep 16, 2024 by Dow Jones
7:00AM ET on Monday Sep 16, 2024 by Dow Jones
Sep 9, 2024
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024, from 7:00AM ET on Monday Sep 09, 2024 by Dow Jones
7:00AM ET on Monday Sep 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Zentalis Pharmaceuticals Inc | 262.4M | -1.4x | --- |
Corbus Pharmaceuticals Holdings Inc | 258.8M | -3.7x | --- |
Rezolute Inc | 270.2M | -3.8x | --- |
Zura Bio Ltd | 253.2M | -8.0x | --- |
ESSA Pharma Inc | 275.5M | -10.2x | --- |
Black Diamond Therapeutics Inc | 249.2M | -2.9x | --- |
Company Information
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Contact Information
- Headquarters
- 10275 Science Center Drive, Suite 200SAN DIEGO, CA, United States 92121
- Phone
- 858-263-4333
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- David Johnson
- President, Interim Chief Financial Officer, Interim Treasurer, Executive Director
- Cam Gallagher
- President, Chief Executive Officer, Director
- Kimberly Blackwell
- Chief Scientific Officer
- Mark Lackner,
- Chief Medical Officer
- Diana Hausman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $262.4M |
|---|---|
Revenue (TTM) | $40.6M |
Shares Outstanding | 71.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.70 |
EPS | $-2.75 |
Book Value | $6.18 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 6.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -543.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
